Market capitalization | CHF835.83m |
Enterprise Value | CHF827.12m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 15.74 |
P/S ratio (TTM) P/S ratio | 15.91 |
P/B ratio (TTM) P/B ratio | 13.66 |
Revenue growth (TTM) Revenue growth | 157.23% |
Revenue (TTM) Revenue | CHF52.54m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Kuros Biosciences:
1 Analyst has issued a forecast Kuros Biosciences:
Jun '24 |
+/-
%
|
||
Revenue | 53 53 |
157%
157%
|
|
Gross Profit | 45 45 |
183%
183%
|
|
EBITDA | -2.30 -2.30 |
76%
76%
|
EBIT (Operating Income) EBIT | -4.92 -4.92 |
60%
60%
|
Net Profit | -8.89 -8.89 |
44%
44%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.
Head office | Switzerland |
CEO | Christopher Fair |
Employees | 5 |
Founded | 2000 |
Website | kurosbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.